This website is for UK Healthcare Professionals only

R&R Magazine

 

Issue 1: Summer 2021

Issue 2: Spring 2022

Expert Opinion

 

Dr Martin Perry
SELECT COMPARE Overview

Prof Philip Conaghan
SELECT COMPARE Risk benefit analysis

Clinical Summary Videos

 

SELECT COMPARE 

SELECT NEXT 

SELECT MONOTHERAPY 

SELECT BEYOND 

Clinical Summaries

SELECT COMPARE 

View a summary of the SELECT COMPARE clinical trial - RINVOQ versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate.           

SELECT MONOTHERAPY 

View a summary of the SELECT MONOTHERAPY clinical trial - RINVOQ as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate.

SELECT NEXT 

View a summary of the SELECT NEXT clinical trial - Safety and efficacy of RINVOQ in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.              

SELECT BEYOND 

View a summary of the SELECT BEYOND clinical trial - Safety and efficacy of RINVOQ in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs.            

SELECT CHOICE

View a summary of the SELECT CHOICE clinical trial - Trial of upadacitinib or abatacept in rheumatoid arthritis.           

UK-UPAD-220199. Date of preparation: August 2022

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com